Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy
Final results of the Austrian PegHope study
- 12.09.2017
- original article
Erschienen in:
- Verfasst von
- Prof Michael Gschwantler, MD
- Hermann Laferl, MD
- Prof Wolfgang Vogel, MD
- Wolfgang Korak, MD
- Stephan Moser, MD
- Prof Harald Hofer, MD
- Bernhard Bauer, MD
- Michael Schleicher, MD
- Barbara Bognar, MD
- Martin Bischof, MD
- Prof Rudolf Stauber, MD
- Prof Andreas Maieron, MD
- Prof Peter Ferenci, MD
- Austrian Hepatitis Study Group
- Erschienen in
- Wiener klinische Wochenschrift | Ausgabe 1-2/2018
Summary
Background
Patients with a history of intravenous drug abuse included in an official opioid substitution program represent an important subgroup of patients with chronic hepatitis C. The objective of this study was to assess the efficacy of and adherence to treatment with peginterferon and ribavirin in Austrian patients on stable opioid substitution therapy (OST).
Methods
This prospective, multicenter, observational, non-interventional trial (clinicaltrials.gov identifier, NCT01416610) included treatment-naïve patients with chronic hepatitis C on OST. Treatment consisted of peginterferon alpha-2a (PEGASYS®, 180 µg/week) plus ribavirin (COPEGUS®, 1000/1200 mg/day in genotypes (GT) 1/4 and 800 mg/day in GT 2/3) for 24–72 weeks, according to GT and viral response.
Results
The intention-to-treat (ITT) population comprised 88 patients. Mean duration of therapy was 6.0 ± 2.8 months. Treatment was discontinued earlier than planned in 34 out of 88 patients (39%), mainly because of poor adherence or side effects of treatment. At the end of treatment 65/88 patients (74%) were PCR negative. During follow-up, 5 patients relapsed. Only 44/88 patients (50%) could be evaluated 24 weeks after the end of treatment. Sustained virologic response 24 weeks after end of therapy (SVR24) was documented in 39/88 patients (44%). If only patients were considered who finished treatment as planned and for whom results at follow-up week 24 were available, the SVR24 rate was 89% (32/36).
Conclusion
Despite favorable prognostic factors, such as young age and a high proportion of GT3, SVR rates were low in this cohort of patients receiving OST, the main reason being poor adherence; however, in those patients completing treatment, the SVR rate was high.
Anzeige
- Titel
-
Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy
Final results of the Austrian PegHope study - Verfasst von
-
Prof Michael Gschwantler, MD
Hermann Laferl, MD
Prof Wolfgang Vogel, MD
Wolfgang Korak, MD
Stephan Moser, MD
Prof Harald Hofer, MD
Bernhard Bauer, MD
Michael Schleicher, MD
Barbara Bognar, MD
Martin Bischof, MD
Prof Rudolf Stauber, MD
Prof Andreas Maieron, MD
Prof Peter Ferenci, MD
Austrian Hepatitis Study Group
- Publikationsdatum
- 12.09.2017
- Verlag
- Springer Vienna
- Erschienen in
-
Wiener klinische Wochenschrift / Ausgabe 1-2/2018
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671 - DOI
- https://doi.org/10.1007/s00508-017-1263-2
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.